Distinguished in Dyschromatosis Universalis Hereditaria

Shuping Guo

85 South Jiefang Road, 
Taiyuan, CN 
Distinguished in Dyschromatosis Universalis Hereditaria
85 South Jiefang Road, 
Taiyuan, CN 
OverviewLocationsClinical Research

Overview

Shuping Guo practices in Taiyuan, China. Guo is rated as a Distinguished expert by MediFind in the treatment of Dyschromatosis Universalis Hereditaria. Their top areas of expertise are Dyschromatosis Universalis Hereditaria, Psoriasis, Plaque Psoriasis, and Nevoid Basal Cell Carcinoma Syndrome.

Their clinical research consists of co-authoring 31 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Dyschromatosis Universalis Hereditaria.

Locations

85 South Jiefang Road, Taiyuan, 030000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: June 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

31 Total Publications

Wolf's isotopic response of eczema after herpes zoster infection: case report and literature review.
Wolf's isotopic response of eczema after herpes zoster infection: case report and literature review.
Journal: Frontiers in medicine
Published: September 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Guo's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile